Psychiatry
Pipeline by Development Stage
Psychiatry is a $6.9B mature market dominated by peak-stage antipsychotics and emerging neuropsychiatric treatments with significant patent cliff exposure.
Key Trends
- Heavy concentration in schizophrenia and bipolar disorder treatments with limited pipeline diversity
- Major patent cliffs 2027-2031 threatening $2.7B+ in revenue from top products
- Commercial hiring surge led by AbbVie and Compass Pathways signals market consolidation and specialty repositioning
Career Verdict
Psychiatry offers stable mid-career opportunities in commercial and regulatory roles but limited R&D growth; best suited for professionals comfortable managing mature product portfolios rather than pioneering new therapies.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 26% | Peak | Stable | 4.7yr |
| 2 | INGREZZA (valbenazine) | Neurocrine Biosciences | $1.7B | 25% | Peak | Stable | 14.3yr |
| 3 | VRAYLAR (cariprazine) | AbbVie | $936M | 14% | Peak | Stable | 3.9yr |
| 4 | REXULTI (brexpiprazole) | Otsuka | $630M | 9% | Peak | Stable | 6.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 8% | Peak | Stable | 15.6yr |
Drug Class Breakdown
stable with upcoming patent cliff pressure
niche indication dominance (Huntington's disease)
mechanism of action unclear for several agents
adjunctive therapy positioning growing
sleep disorder segment stable
fragmented and declining
Career Outlook
StablePsychiatry represents a steady but non-growth therapeutic area dominated by mature, peak-stage products facing near-term patent cliffs. Employment remains concentrated in commercial, regulatory, and manufacturing support roles rather than R&D innovation. Career progression depends heavily on comfortable portfolio management and stakeholder engagement in a defensive market environment.
Breaking In
Target commercial roles at AbbVie, Compass Pathways, or established players; psychiatry entry-level positions prioritize sales execution and account management over research exposure.
For Experienced Professionals
Experienced professionals should consider lateral moves to Compass Pathways (psychedelics repositioning) or emerging specialty care models rather than traditional pharma roles, as mature product portfolios offer limited strategic growth.
In-Demand Skills
Best For
Hiring Landscape
111 total psychiatry jobs are heavily skewed toward commercial roles (33 positions, 30% of total), with AbbVie leading hiring at 26 jobs and Compass Pathways showing aggressive expansion at 22 positions. Regulatory Affairs (4 jobs) and manufacturing/engineering support (8 and 4 jobs respectively) are minimal, signaling mature commercial-stage portfolio management rather than development-stage investment.
Top Hiring Companies
By Department
Commercial roles offer highest earning potential and job volume, but limited R&D positions indicate fewer advancement pathways for research-focused professionals.
Competitive Landscape
0 companies ranked by most advanced pipeline stage
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.